A single-center, cross-sectional, longitudinal study was conducted to determine the prevalence, annual incidence, and clinical risk factors for skin cancer in a white renal transplant population. One hundred eighty-two white patients (95% of population) with functioning allografts, a mean age at transplantation of 38.9 ؎ 15.6 (SD) years, and a mean follow-up of 8.5 ؎ 6.3 years were interviewed and examined between May 1997 and June 1999. All case notes were carefully reviewed. Since transplantation, 16.5% of the patients had developed nonmelanoma skin cancer; 15.4%, actinic keratoses (AK); 53%, viral warts; and 1.6%, lentigo maligna melanoma (n ‫؍‬ 3). Thirty-nine percent of the tumors were detected as a consequence of this study, and 20% of these occurred on covered body sites. The squamous cell (SCC)-basal cell carcinoma (BCC) ratio was 3.8:1. Eighty-two percent of the patients were examined a second time 12 months after the initial assessment. Using these data to identify new lesions, the annual incidence was calculated at 6.5%, increasing to 10.5% at more than 10 years posttransplantation. Duration of immunosuppression, older age at transplantation, presence of AK, male sex, and outdoor occupation were significantly associated with both SCC and BCC; SCC alone was associated with a history of having smoked tobacco. Early identification of those at greatest risk using a clinical risk profile may allow the development of more structured preventative and surveillance strategies than currently exist.
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N

ONMELANOMA skin cancer (NMSC)
causes significant morbidity and mortality in renal transplant recipients. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Studies examining skin cancer risk have reported that the prevalence of skin cancer varies from 5% to 22%. 12, 13 The actual cancer risk may have been underestimated because of the method limitations of retrospective case note review, incomplete reporting to registry databases, or sampling errors caused by variable patient selection because few studies have characterized an entire transplant population. [1] [2] [3] 5, 6 Because skin cancer is likely to place a significant and increasing burden on health care providers, it is important that the nature and scale of the problem is accurately assessed to target high-risk patients for follow-up and plan for the provision of future clinical services.
We conducted a cross-sectional and longitudinal study with the aim of accurately establishing the prevalence and annual incidence of skin cancer in a stable UK renal transplant population and to determine clinical factors associated with risk. Although some studies have examined factors that influence skin cancer risk, none to our knowledge have investigated associations with number of skin cancer lesions. We therefore examined associations between putative risk factors and both skin cancer risk and number of tumors.
PATIENTS AND METHODS
Patients
A cross-sectional study of all renal transplant recipients with functioning allografts followed up at the North Staffordshire Hospital, Staffordshire, UK (n ϭ 199), was performed between May 1997 and June 1999. Local hospital ethics committee approval and written informed consent were obtained. Three patients withheld consent, 7 patients were lost to follow-up, and 7 patients with skin types V and VI (none of whom had skin tumors) were excluded, leaving a cohort of 182 white renal transplant recipients (95%).
Therapeutic Strategies
The current immunosuppressive regimen comprises triple therapy with prednisolone (20 mg/d), azathioprine (2 mg/kg; Imuran; Wellcome, Stockley Park, Middlesex, UK), and cyclosporine (to March 1996, Sandimmune; Sandoz, Basel, Switzerland; from March 1996, Neoral; Novartis, Basel, Switzerland; target trough level, 150 to 200 ng/mL) and was the standard since 1989. Prednisolone has been successfully withdrawn from 56% of the patients posttransplantation, leaving a maintenance dual immunosuppressive regimen with azathioprine (1 to 1.5 mg/kg) and cyclosporine (target trough level, 120 to 150 ng/mL) or tacrolimus (target trough level, 5 to 10 ng/mL). The median time from transplantation to prednisolone withdrawal was 1.08 years (range, 0.36 to 3.17 years). Previous maintenance protocols were based on prednisolone (10 mg/d) and, until 1984, azathioprine (1 mg/kg), or between 1984 and 1989, cyclosporine (target trough level, 150 ng/mL). Standard acute rejection episodes are managed with methylprednisolone (500-mg pulses on 3 consecutive days; UpJohn, Milton Keynes, UK). Steroidresistant rejection is treated with pulsed antithymocyte globulin (ATG; Fresenius, Hamburg, Germany) or conversion to tacrolimus since 1996. Three patients were administered immunosuppression before transplantation for their underlying renal disease. Twelve of the currently functioning allografts were from living related donors, and there was one multiorgan recipient.
Study Parameters
A structured questionnaire was completed by a single dermatologist (H.M.R.) at the initial interview with the patients in a dedicated clinic running in parallel with the weekly renal transplantation follow-up clinic. The investigator was blinded to previous dermatological records at the time of interview and examination.
Demographic information included age, sex, smoking history, skin types I through VI 14 (internationally recognized Fitzpatrick classification: skin types I [fair skin that always burns and never tans] to VI [permanently deeply pigmented]), natural hair and eye color at the age of 21 years, years worked in an indoor or outdoor occupation (outdoor defined as Ͼ50% of the time usually spent outdoors), residence (Ͼ3 months), holidays abroad in tropical or subtropical climates, sunbed use, recalled childhood sunburn episodes (painful erythema Ն48 hours), sunscreen use, arsenic exposure, and history of malignancy in a first-degree relative. In addition to occupational exposure, sun exposure was determined from data on average number of hours spent outdoors (weekends and weekdays were separately assessed) during the ages 0 to 40, 40 to 60, and older than 60 years. Cumulative sun exposure was then calculated as years spent outdoors. Sunbathing habits were examined by determining frequency of sunbathing (never, rarely, occasionally, frequently) during the same periods. These were scored (0, never; 1, rarely; 2, occasionally; 3, frequently), and the cumulative score was calculated.
Unclothed patients were examined initially by the same dermatologist (H.M.R.). Selective anogenital examination was performed on consenting patients who expressed concerns or who gave a positive history of previous or current anogenital lesions. Potentially malignant lesions, those of uncertain diagnosis, or those with atypical features (usually induration, erythema, or inflammation at the base) were biopsied. Only histologically proven malignancies were considered for the purposes of this study, but a clinical diagnosis of warts and actinic keratoses (AK) was accepted. Recurrent lesions were excluded from the analysis of primary tumors. The opportunity was taken to advise all patients on subsequent self-examination and sun-avoidance measures. Patients requiring further follow-up were transferred to general dermatology clinics.
All case notes and pathology reports were carefully reviewed for details of previous skin cancers. In cases in which dermatological treatment had been received in another center, details were sought from the treating physician. Information was also extracted by a single nephrologist (P.N.H.) on the cause of end-stage renal failure, pretransplantation immunosuppression, time undergoing dialysis, number and date(s) of transplantation(s), immunosuppressant therapy, rejection episodes, and comorbid conditions. The UK Transplant Support Services Authority provided donor and recipient HLA data.
Of the 182 patients recruited onto the study, 150 patients (82%) were screened at a mean time of 1.28 Ϯ 0.36 (SD) years later for the appearance of new lesions in a dedicated transplant skin surveillance clinic. A limited questionnaire and full clinical examination was performed by a single nurse practioner (S.R.) who had completed a 6-month training program with the dermatologist (H.M.R.) who conducted the initial cross-sectional survey. Of patients for whom the second-visit data were not available (n ϭ 32), 3 patients were lost to follow-up, 7 patients died, 5 patients had failure of the graft (and were transferred to hemodialysis), and 17 patients had not yet reached the first anniversary of the initial examination.
Statistical Analysis
The Stata software package (version 5; Stata Corp, College Station, TX) was used for all statistical analyses. Skin cancer risk was examined using the presence of NMSC, squamous cell carcinoma (SCC) alone, and basal cell carcinoma (BCC) alone as end points. Logistic regression analysis was used to examine factors associated with skin cancer risk. Outcome was also assessed in terms of the number of tumors accrued. To determine the factors associated with the number of skin cancers, negative binomial regression analysis was used, normalized for follow-up time, with number of NMSC, SCC, and BCC as outcome measures. A rate ratio, defined as the multiplicative effect of a change in a covariate by 1, was calculated (for these data, usually a change from 0 to 1). Thus, the rate ratio for men (1) against women (0) is the mean number of BCC in men to the mean number of BCC in women when sex alone (ie, not in the presence of other covariates) is considered. In the negative binomial regression, this will change in the presence of other covariates and after normalization for duration of follow-up. Associations with time from transplantation to appearance of the first NMSC was assessed using Cox proportional hazards regression. Data are presented when factors were significantly (P Ͻ 0.05) associated with at least one of these outcome parameters. All other parameters showed P greater than 0.1. Annual incidence rate was calculated as the number of cases at the second examination with new tumors since the first examination/(total number of patients examined * mean interval between first and second examination).
RESULTS
General Patient Characteristics
One hundred eighty-two white renal transplant recipients (95%) followed up at this center were recruited. Clinical characteristics of this group are listed in Table 1 . Native renal diseases were chronic glomerulonephritis in 32%, diabetes mellitus in 3%, hereditary in 12%, reflux nephropathy in 16%, and other causes in 37%. The distribution of maintenance immunosuppressive regimens and pattern of escalated therapy with methylprednisolone and ATG for clinical rejection episodes are listed in Table 1 .
Dermatological Findings
NMSC, AK, and viral warts all increased with increasing duration of immunosuppression (Table 2 ). Thirty patients (16.5%) developed 118 skin cancers since the first transplantation. NMSC (28 invasive and 33 in situ SCC in 20 patients, 53 BCC in 18 patients, and 1 syringocystadenocarcinoma papilliferum) accounted for 97.8% of the tumors, with lentigo maligna melanoma arising in 3 patients (1 of whom also developed NMSC; Fig 1) . Keratoacanthoma was found in 3 patients on a background of multiple AK and invasive SCC. One fifth of all tumors (18.9% of BCC, 15.2% of in situ SCC, and 21.4% of invasive SCC) occurred on surfaces normally covered and exposed to less UV light and had not been previously recognized by a physician or reported by the patient (Table 3) . Sixty-one tumors were newly diagnosed during this study (28 SCC in situ, 17 invasive SCC, 12 BCC, 3 lentigo maligna melanoma, and a malignant sweat gland tumor). Only 2 of these patients were under dermatological review or referral. No metastatic or fatal tumors occurred within the study group. The ratio of newly occurring SCC to BCC was 3.8:1, a reversal of the pattern seen in the general population.
AK occurred in 28 patients (15.4%), with 19 patients newly diagnosed. Eighty percent of AK were confined to sun-exposed sites; the remainder showed widespread hyperkeratotic lesions, usually a mixture of warts and AK. In 50% of the patients, AK were first documented before or at the same time as the first NMSC. One of the 3 patients with lentigo maligna melanoma had AK.
Ninety-five patients (53%) had viral warts. These were confined to the hands and feet in the majority; only 8.2% had truncal warts, 15.4% had head and neck warts, and 3% had anogenital warts. Four of the five patients with anogenital lesions had warts elsewhere.
NMSC Incidence
Of the 150 patients with annual follow-up data, 12 patients developed 38 new skin cancers (4 patients with no prior lesions). The tumors included 6 BCC, 30 SCC (20 in situ SCC, 10 invasive SCC), 1 malignant melanoma (MM), and a syringocystadenocarcinoma papilliferum. For the 150 patients, the overall incidence of new cases per year was 6.5%, increasing to 8.6% in patients at greater than 5 years and 10.5% at greater than 10 years posttransplantation.
Clinical Risk Factors
Significant clinical associations with NMSC risk are listed in Table 4 . Older age at transplantation was significantly associated with increased risk for both SCC and BCC. Male sex showed a significant correlation with NMSC risk, with men at greater risk than women (Table 4) . Examination of the distribution of inherited pigmentary characteristics (skin type, hair and eye color) showed that only green-eyed individuals had a significantly increased risk for SCC (odds ratio [OR], 7.3; P ϭ 0.03) compared with those with brown eyes. The proportion of patients with SCC decreased from 16.7% in patients with skin type I to 6.5% in those with skin type IV, although this did not reach statistical significance. UV exposure was assessed using several measures; years worked in an outdoor occupation in the UK was associated with increased risk for NMSC, particularly BCC, whereas holidays abroad, cumulative sun exposure, and sunbathing were associated primarily with SCC (Table 4) . Smoking history was significantly associated with SCC risk when expressed as either ever having smoked (current plus exsmokers versus never smoked, P ϭ 0.009; OR, 5.4; 95% confidence interval, 1.5 to 19.1) or level of tobacco consumption (P ϭ 0.012; OR, 1.031/pack-year). As expected, patients with AK were at significantly increased risk for both SCC (OR, 56.4; P Ͻ 0.001) and BCC (OR, 24.8; P Ͻ 0.001) compared with those without AK.
Neither hair color, current sunscreen use, sunbed use, episodes of childhood sunburn, family history of skin cancer, time as resident abroad, arsenic exposure, time spent on dialysis, number of transplants, HLA mismatch (number of mismatches at HLA-A, HLA-B, and HLA-D loci and total number of mismatches), nor pretransplantation immunosuppression showed significant associations with NMSC, although in some cases, the numbers were small. No significant association was found between immunosuppressant (mean dose, cumulative dose, and dose per kilogram of body weight of azathioprine, cyclosporine, tacrolimus, and prednisolone) used, number of acute rejection episodes or treatment for rejection (meythylprednisolone or ATG), and skin cancer risk.
Clinical Associations With Number of NMSC
Significant associations were found between the number of skin lesions, listed in Table 5 . As with the presence of skin cancers, age at transplantation and sex were significantly associated with numbers of lesions, both for SCC and BCC. As for SCC risk, green eye color was also associated with increasing numbers of SCC (Table 5) . Of the exposure measures used, only outdoor occupation was associated with number of tumors. The presence of AK and warts was associated with increasing numbers of lesions, particularly SCC, although no significant associations were identified between number of NMSC and presence of keratoacanthoma. All other parameters were not significant. 
Clinical Associations With Time From Transplantation to Appearance of First NMSC
The mean time from transplantation to the appearance of the first NMSC was 7.6 years in patients who developed tumors. The data were further analyzed to identify factors associated with this end point. Age at transplantation (P Ͻ 0.001; hazard ratio [HR] ϭ 1.10/y), smoking history (ever smoked, P ϭ 0.001; HR ϭ 6.1; and pack-years, P Ͻ 0.001; HR ϭ 1.04/pack-year), years spent in an outdoor occupation (P Ͻ 0.001; HR ϭ 1.05/y), cumulative sun exposure (P ϭ 0.003; HR ϭ 1.05/y), sunbathing habits (P Ͻ 0.001; HR ϭ 1.42/unit score), and holidays abroad (P ϭ 0.009; HR ϭ 1.04/wk) were all significantly associated with time from transplantation to appearance of first NMSC. The associations with green eye color (P ϭ 0.092; HR ϭ 2.5) and sex (P ϭ 0.100; HR ϭ 2.4) approached significance. Presence of AK was associated with a significantly reduced time from transplantation to appearance of the first NMSC (P Ͻ 0.001; HR ϭ 4.2; Fig 2) .
DISCUSSION
Initial reports of increased prevalence of skin cancer after renal transplantation originated from countries with high UV exposure. 1, 4 This study shows that 16.5% of a UK transplant population are affected, increasing to 27.6% of those on immunosuppression therapy for 10 years or more. Excess skin cancer is clearly a significant problem in more temperate climates. To our knowledge, only two other studies have presented a prospective cross-sectional cohort of renal allograft recipients and found a prevalence of 5% and 22%. 12,13 Cross-sectional analysis will exclude patients with allograft failure or death with a functioning graft; consequently, our data may have underestimated the overall risk for skin cancer associated with renal transplantation. A prospective longitudinal study is not available in the literature and is the only means of determining the overall incidence rate. We have prospectively examined 82% of our patients and identified an annual incidence rate of 6.5%. However, the incidence rate increased with time posttransplantation, and only one patient developed a new tumor at less than 5 years posttransplantation, supporting the view that incidence is dependent on duration of immunosuppression.
The reversal of the usual SCC-BCC ratio from approximately 1:4 in the general population to 3.8:1 in this transplant population is notable and confirms previous findings describing a ratio between 2:1 and 15:1. However, it is important to realize that the risk for BCC remains at approximately 20 times that observed in the local general population, and a significant proportion are located on sites not exposed to UV light or readily recognized by the patient or nephrologist. Furthermore, Australian studies have shown the risk for metastasis and death from SCC to be significantly greater than that in the general population. 2, 15, 16 However, it has been suggested that although causing significant morbidity, SCC arising in transplant recipients in temperate climates may not show the same aggressive behavior 12 because of reduced UV exposure. Although no metastatic or recurrent tumors have been seen in this series, careful prospective follow-up is needed to monitor patients with NMSC because highly aggressive and problematic SCC have been reported by other European investigators. 13, 17 AK are considered low-grade dysplasias in the immunocompetent host, with only a small propensity for malignant change, often going unreported and untreated with little consequence. After transplantation, AK, in situ SCC, and keratoacanthoma occurred more frequently, were more likely to progress to invasive SCC, 2, 18 and acted as a marker of increased skin cancer risk. This observation was strongly supported for AK in both forms of NMSC in this study, but the association with SCC was greater than twice that observed for BCC and fourfold more if greater than 10 AKs were present. Consequently, the early identification, treatment, and dermatological supervision of patients with such premalignant lesions may reduce the frequency with which previously unrecognized large or invasive tumors present clinically. Viral warts and NMSC both increased with duration of immunosuppression and showed a predilection for sun-exposed sites. However, the association between viral warts and skin cancer risk was only identified in patients with greater than 10 warts and with SCC rather than BCC. The exact role of human papilloma virus infection in posttransplantation NMSC still remains unclear; the diverse human papilloma virus types identified are unlikely carcinogens in their own right. 19 Individual susceptibility to skin cancer is likely to be determined by multiple and interacting factors, including immunosuppression, UV exposure, and genetic susceptibility. It would be clinically useful to identify those patients at greatest risk for skin cancer to target preventative measures and treatment. A number of readily identifiable features in our population may allow a patient to be deemed high risk, including male sex, older age, outdoor occupation, duration of immunosuppression, and smoking history. In keeping with findings in the general population, increasing years spent working in an outdoor occupation in the UK, even when corrected for age and sex, were associated with NMSC, particularly BCC. We also showed associations between NMSC risk (particularly SCC) and other markers of UV exposure (eg, holidays abroad, cumulative sun exposure, sunbathing habits), but not with sunburn episodes in childhood or residence in a hot climate.
The mechanism of UV-induced carcinogenesis is complex and involves a combination of UV-induced immune suppression, generation of reactive oxygen species, and DNA damage. 20 Individual ability to handle these insults will influence outcome. Renal transplant recipients living in Queensland, Australia, have a risk for skin cancer five times that observed in more temperate climates, with a cumulative incidence of 23% at 5 years and 44% at 9 years posttransplantation. 5, 21 Other Australian data suggest that pretransplantation UV exposure is more important than posttransplantation exposure in determining skin cancer risk, 22 and that level of sun exposure before the age of 30 years may be critical. 23 Our data suggest that exposure during each of the three periods studied was equally important in determining the risk for NMSC (data not shown). Retrospective quantification of individual lifetime UV exposure is difficult, with significant recall error and poor reproducibility. Not surprisingly, disparate results emerged from two other UK studies examining UV exposure and skin cancer risk posttransplantation despite similar methods. 1, 3 Pigmentary factors are also known to influence NMSC risk in the general population 24 ; eye color and skin type influence BCC and SCC risk, and hair color influences SCC risk. We found that green-eyed individuals are at increased risk for SCC, and skin type IV appears to confer some degree of protection, although this did not reach statistical significance. We confirmed that men are at greater risk; estrogens are known to stimulate melanin production and may confer a degree of protection in women. 25 The association between smoking and SCC is of particular interest and is in contrast with data from Australia suggesting no link between SCC posttransplantation and tobacco smoking. 22 In the general population, smoking is a recognized risk factor for SCC of the lip, 26 although studies of skin cancer have shown conflicting results. 24, 27 No previous study has examined factors that influence the number of NMSC in transplant recipients. We have identified similar factors associated with numbers and time from transplantation to the appearance of the first NMSC as with susceptibility, although some markers of UV exposure were less important and the presence of keratoacanthoma did not achieve significance. We previously showed that age and sex influence the number of lesions in immunocompetent BCC patients. 28 Furthermore, we also previously showed that blue and green eye color is associated with larger numbers of BCC, 28 a finding reproduced in this study of transplant recipients for SCC but not significantly for BCC. In contrast to that detected in immunocompetent BCC patients, we did not identify an association between skin type and number of NMSC in transplant recipients. As expected, the presence of AK was associated with more NMSC, particularly SCC, with greater than 10 AK associated with markedly increased numbers of SCC. The absence of an association between keratoacanthoma and number of NMSC may reflect small numbers of patients with these lesions.
Posttransplantation survival and the numbers of transplant recipients with cutaneous malignancy are likely to continue to escalate as the cohort of solid-organ transplant recipients increases. This reflects improved early graft survival rates and reduced rejection risk as a result of more effective immunosuppressive agents. Although azathioprine and its metabolites have been specifically implicated in the cause of posttransplantation skin cancer in the past, 29 we found no significant difference in risk between the various immunosuppressive regimens used, supporting the view that immunosuppression load rather than the specific agent used confers the risk.
UV exposure is the main risk factor that can be modified. Many transplant recipients undergoing long-term follow-up fail to take adequate precautions against UV, and patient education regarding sun avoidance and sunscreens should be incorporated into the pretransplantation assessment 30 and reinforced regularly posttransplantation. We suggest that as a minimum, the skin of every patient should be examined and sun-avoidance advice reinforced at least annually during routine follow-up. Although there is no evidence to support screening the general population for skin cancer, high-risk groups may benefit. Individual risk assessment should be routine, and those at a particularly high risk, such as those with AK or previous skin tumors, require more intensive monitoring and should be followed up at least every 3 months. Clinical experience suggests some patients may need to be seen as frequently as every 4 to 6 weeks. Furthermore, recent evidence suggests that some patients with multiple tumors may benefit from long-term, low-dose systemic retinoid therapy. 31 The importance of systematic skin surveillance increases with time from transplantation. Although the majority of tumors in our population occurred on sun-exposed sites, it is tempting but unacceptable to examine only these high-risk sites in a busy clinic because this approach will result in missing 20% of the tumors. Additionally, it is notable that in the general population, patients with truncal BCC have been found to be at particular risk for multiple BCC. 32 Patients must therefore be examined fully unclothed, although selective anogenital examination will probably suffice; anogenital warts were identified in 4 patients in this series, similar to the 2% incidence of anogenital warts found on systematic examination of 752 renal transplant recipients. 33 NMSC poses a significant clinical problem posttransplantation, even in temperate climates. There is no standard practice in the UK with regard to follow-up of renal transplant recipients with respect to skin cancer risk. We have previously shown that fewer than half the UK renal transplant centers have a structured approach to patient education, and only a minority offer a form of dermatological screening. 34 Similar concerns have been raised in Pennsylvania, where 41% of renal allograft recipients were unable to recall specific skin cancer education and 52% were interested in a formal screening program. 35 In line with the targets set in the Health of the Nation document 36 to reduce the incidence of skin cancer, there is an urgent need for such strategies to be developed. The development of combined dermatology and transplantation clinics would facilitate the early recognition and treatment of those at greatest risk.
